LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

GO Therapeutics

GO Therapeutics is applying the latest advances in Glycobiology to create cancer drugs that are more potent and less toxic. Our “Hybrid Epitope” tumor-specific antibodies can be used in multiple modalities such as antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies. GO Therapeutics’ team features some of the leading authorities in the science of the Cancer Glycoproteome. 

  • Constantine Theodoropulos Co-Founder and Chief Executive Officer
  • Thayer White, PhD Co-Founder and Chief Scientific Officer
  • Hans Wandall, MD, PhD Senior Scientific Consultant
  • Henrik Clausen, SciD Senior Scientific Consultant